A Phase II Study of Cabozantinib (XL184) for Plexiform Neurofibromas in Subjects With Neurofibromatosis Type 1 Age 16 Years or Greater
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Jun 2017
At a glance
- Drugs Cabozantinib (Primary)
- Indications Plexiform neurofibroma
- Focus Therapeutic Use
- 26 Sep 2016 Planned End Date changed from 1 Oct 2017 to 1 Oct 2019.
- 26 Sep 2016 Planned primary completion date changed from 1 May 2017 to 1 May 2018.
- 10 Sep 2016 Status changed from recruiting to active, no longer recruiting.